Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
O75718
UPID:
CRTAP_HUMAN
Alternative names:
-
Alternative UPACC:
O75718; B2RBL6
Background:
Cartilage-associated protein plays a pivotal role in the structural integrity of connective tissues, primarily through its necessary function in the 3-hydroxylation of fibrillar collagen prolyl residues. This enzymatic activity is crucial for the proper formation and maintenance of collagen, a key component of the extracellular matrix.
Therapeutic significance:
The protein's involvement in Osteogenesis imperfecta 7, a severe connective tissue disorder, underscores its potential as a therapeutic target. Effective modulation of Cartilage-associated protein activity could lead to breakthrough treatments for patients suffering from this debilitating condition, characterized by bone fragility and susceptibility to fractures.